TCM
NBIX icon

TimesSquare Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

TimesSquare Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-868,812
Closed -$62M – 233
2018
Q4 		$62M Sell
868,812
-87,700
-9% -$8.4M 0.54% 75
2018
Q3 		$118M Sell
956,512
-525,100
-35% -$59.6M 0.78% 32
2018
Q2 		$146M Sell
1,481,612
-318,450
-18% -$28.5M 0.97% 16
2018
Q1 		$149M Sell
1,800,062
-569,988
-24% -$48.1M 1.02% 15
2017
Q4 		$184M Buy
2,370,050
+21,950
+0.9% +$1.5M 1.21% 9
2017
Q3 		$144M Buy
2,348,100
+32,727
+1% +$1.73M 0.96% 16
2017
Q2 		$107M Buy
2,315,373
+1,735,700
+299% +$84.2M 0.69% 38
2017
Q1 		$25.1M Buy
579,673
+48,573
+9% +$2.08M 0.16% 199
2016
Q4 		$20.6M Buy
531,100
+27,800
+6% +$1.26M 0.14% 207
2016
Q3 		$25.5M Buy
503,300
+66,000
+15% +$3.29M 0.16% 198
2016
Q2 		$19.9M Buy
+437,300
New +$20.1M 0.13% 201

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TimesSquare Capital Management's NBIX Position: Q1 2019 in Review

TimesSquare Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2019, closing a stake of 868,812 shares — an estimated $62M sold.

TimesSquare Capital Management first reported a position in NBIX in Q2 2016 and held it in 11 quarters. The position peaked at $184M in Q4 2017. 325 funds tracked by Wall St. Rank hold NBIX as of Q1 2019.

  • TimesSquare Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2019 after selling out during the quarter.
  • TimesSquare Capital Management sold 868,812 Neurocrine Biosciences shares in Q1 2019, an estimated $62M.
  • TimesSquare Capital Management first reported a position in Neurocrine Biosciences in Q2 2016 and held it in 11 quarters.
  • TimesSquare Capital Management's Neurocrine Biosciences position peaked at $184M in Q4 2017.
  • 325 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2019.

Based on TimesSquare Capital Management's 13F filing for Q1 2019, filed 10 May 2019.